MSD Korea exceeded KRW 20 billion annual sales for hyperlipidemia complex Atozet
MSD Korea(CEO Avi BenShoshan) announced on the 6th that the hyperlipidemia therapy ‘Atozet(generic name: ezetimibe/atorvastatin)’ made annual sales of KRW 20 billion and recorded the top sales in the statin+ezetimibe complex market.
The market of statin+ezetimibe complex for hyperlipidemia treat...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
